Evidence map›Paper›PMID 32077785›Full record

ReviewMetabolic syndrome and related disorders2020

Role of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Oxidative Stress-Associated Metabolic Diseases.

Seonwook Kim, Venkateswaran Subramanian, Ahmed Abdel-Latif, Sangderk Lee

Open access · greenAbstract readReview
In one paragraph

Review in Metabolic syndrome and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. A genome-wide association meta-analysis of all-cause and vascular dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Pooled it
  2. Review
  3. Article
  4. CD44, ACAN, PLVAP, and HBEGF Emerged as Potential Biomarkers in Diabetic Retinopathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Seonwook KimSaha Cardiovascular Research Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Venkateswaran SubramanianSaha Cardiovascular Research Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Ahmed Abdel-LatifSaha Cardiovascular Research Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Sangderk LeeSaha Cardiovascular Research Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
University of Kentucky · US

Funding

Role of MP-HBEGF-EGFR signaling for inflammatory action of oxidized phospholipidsR00HL105577 · NHLBI · UNIVERSITY OF KENTUCKY · PI LEE, SANGDERK · 2013 to 2015
$718k
Role of MP-HBEGF-EGFR signaling for inflammatory action of oxidized phospholipidsK99HL105577 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEE, SANGDERK · 2011 to 2012
$180k
NHLBI NIH HHS K99 HL105577NHLBI NIH HHS R00 HL105577
6 · The paper itself

Abstract

Heparin-binding EGF-like growth factor (HB-EGF) is an EGF family member that interacts with epidermal growth factor receptor (EGFR) and ERBB4. Since HB-EGF was first identified as a novel growth factor secreted from a human macrophage cell line, numerous pathological and physiological functions related to cell proliferation, migration, and inflammation have been reported. Notably, the expression of HB-EGF is sensitively upregulated by oxidative stress in the endothelial cells and functions for auto- and paracrine-EGFR signaling. Overnutrition and obesity cause elevation of HB-EGF expression and EGFR signaling in the hepatic and vascular systems. Modulations of HB-EGF signaling showed a series of protections against phenotypes related to metabolic syndrome and advanced metabolic diseases, suggesting HB-EGF as a potential target against metabolic diseases.

Indexed as

AnimalsAtherosclerosisCardiometabolic Risk FactorsDyslipidemiasHeparin-binding EGF-like Growth FactorHumansInsulin ResistanceMetabolic DiseasesOxidative StressPhenotypeSignal TransductionHeparin-binding EGF-like Growth Factoratherosclerosisendothelial cellsHB-EGFmetabolic syndromeNAFLD

Identifiers

PMID32077785
PMCPMC7196370
OpenAlexW3008662484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.